ClinicalTrialsFinder
RecruitingPhase 4NCT07654829

Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema

Sponsor

KalVista Pharmaceuticals, Ltd.

Enrollment

100 participants

Start Date

Aug 17, 2026

Study Type

INTERVENTIONAL

Conditions

Hereditary Angioedema

Summary

This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KVD900 600 mg for people with hereditary angioedema. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKVD900 600 mg

KVD900 Tablet 600 mg (2 x 300 mg)

Locations(1)

KalVista Investigative Site

Colorado Springs, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07654829

Related Trials

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT0696021351 locations

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT0680665711 locations

Institutional Registry of Rare Diseases

NCT065737231 location